These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30947406)

  • 1. Exanthematous Rash With Lurasidone in an Elderly Woman With Schizoaffective Disorder.
    Hafeez ZH
    Prim Care Companion CNS Disord; 2019 Mar; 21(2):. PubMed ID: 30947406
    [No Abstract]   [Full Text] [Related]  

  • 2. Lurasidone-Associated Neuroleptic Malignant Syndrome.
    Lee M; Marshall D; Saddichha S
    J Clin Psychopharmacol; 2017 Oct; 37(5):639-640. PubMed ID: 28806387
    [No Abstract]   [Full Text] [Related]  

  • 3. Lurasidone-Induced Mania.
    Ward HB; Almeida M
    Prim Care Companion CNS Disord; 2019 Jul; 21(4):. PubMed ID: 31298818
    [No Abstract]   [Full Text] [Related]  

  • 4. Lurasidone-Induced Rabbit Syndrome: A Case Report.
    Reichenberg JL; Ridout KK; Rickler KC
    J Clin Psychiatry; 2017 May; 78(5):e553. PubMed ID: 28570801
    [No Abstract]   [Full Text] [Related]  

  • 5. Lurasidone-Induced Dystonia.
    Tibrewal P; Cheng R; Bastiampillai T; Dhillon R; Okungu A; Campbell J
    Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28682525
    [No Abstract]   [Full Text] [Related]  

  • 6. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
    Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
    Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone for schizophrenia.
    Drug Ther Bull; 2015 Mar; 53(3):30-2. PubMed ID: 25765597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Honciuc M; Llorca PM
    Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
    McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible Lurasidone-Associated Dose-Dependent QTc Prolongation in First-Episode Psychosis.
    Naguy A; Al-Khadhari S; Pridmore S
    Psychopharmacol Bull; 2022 Jun; 52(3):68-71. PubMed ID: 35815172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lurasidone associated neutropenia.
    Singh S; Ahmad H; John AP
    Aust N Z J Psychiatry; 2017 Oct; 51(10):1055. PubMed ID: 28478684
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders.
    Findling RL; Goldman R; Chiu YY; Silva R; Jin F; Pikalov A; Loebel A
    Clin Ther; 2015 Dec; 37(12):2788-97. PubMed ID: 26631428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
    Potkin SG; Ogasa M; Cucchiaro J; Loebel A
    Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer-Term Effectiveness and Tolerability of Adjunctive Open Lurasidone in Patients With Bipolar Disorder.
    Miller S; Do D; Gershon A; Wang PW; Hooshmand F; Chang LS; Ketter TA
    J Clin Psychopharmacol; 2018 Jun; 38(3):207-211. PubMed ID: 29620693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression.
    Modugula H; Kumar A
    CNS Neurol Disord Drug Targets; 2020; 19(2):109-114. PubMed ID: 32124704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder.
    Loebel A; Brams M; Goldman RS; Silva R; Hernandez D; Deng L; Mankoski R; Findling RL
    J Autism Dev Disord; 2016 Apr; 46(4):1153-63. PubMed ID: 26659550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Series Reports on Lurasidone-Associated Mania.
    Doan LA; Williams SR; Takayesu A; Lu B
    J Clin Psychopharmacol; 2017 Apr; 37(2):264-266. PubMed ID: 28225748
    [No Abstract]   [Full Text] [Related]  

  • 19. A Case of Emergent Restless Legs Syndrome With Lurasidone Therapy.
    Ghori AK; Sajatovic M; Tampi RR
    J Clin Psychopharmacol; 2016 Jun; 36(3):293-4. PubMed ID: 27035496
    [No Abstract]   [Full Text] [Related]  

  • 20. Lurasidone-induced anemia: Is there a need for hematological monitoring?
    Kirpekar VC; Faye AD; Bhave SH; Tadke R; Gawande S
    Indian J Pharmacol; 2019; 51(4):276-278. PubMed ID: 31571715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.